Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Editorial
Nature Reviews Drug Discovery 7, 105 (1 February 2008) | doi:10.1038/nrd2529
The drought continues
Abstract
Last year, the number of novel drugs approved by the US FDA was again close to an all-time low. Collaborative efforts to enhance the application of emerging science in drug development and regulation deserve particular attention, and, most importantly, resources if the drought in drug approvals is to be brought to an end soon.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
